Journal
ENDOCRINE PRACTICE
Volume 22, Issue 9, Pages 1111-1118Publisher
AMER ASSOC CLINICAL ENDOCRINOLOGISTS
DOI: 10.4158/EP161435.ESGL
Keywords
-
Categories
Funding
- Amgen Inc
- NPS Pharmaceuticals
- NASA-JSC
- Amgen
- Merck
- Eli Lilly and Company
- Opko Health
- Novartis
- GE Healthcare Lunar
- NPS Pharmaceuticals, Inc.
- Gilead Sciences
- Radius Health
- AgNovos
- Radius Pharma
- Roche
- Ultragenyx
- Alexion
- Boehringer Ingelheim
- Immunodiagnostics
- Merck Serrano
- National Bone Health Alliance
- Roche Diagnostics
- Regeneron
- Daiichi Sankyo
- Elsevier
- Cystic Fibrosis Foundation
- NIH
- Sanofi
- Sprout
- Editorial Board for the Harvard Health Letter
- Metrowest Medical Center
- Beth Israel Deaconess Medical Center, Needham
- Beth Israel Deaconess Medical Center, Boston
- Boston University Dental School and Medical School
- MCE Conferences
- Celgene Corporation
Ask authors/readers for more resources
The American Association of Clinical Endocrinologists/American College of Endocrinology Medical Guidelines for Practice are systematically developed statements to assist healthcare professionals in medical decision-making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available